Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr 27;9(5):41.
doi: 10.3390/cancers9050041.

Targeting the ATR-CHK1 Axis in Cancer Therapy

Affiliations
Review

Targeting the ATR-CHK1 Axis in Cancer Therapy

Stuart Rundle et al. Cancers (Basel). .

Abstract

Targeting the DNA damage response (DDR) is a new therapeutic approach in cancer that shows great promise for tumour selectivity. Key components of the DDR are the ataxia telangiectasia mutated and Rad3 related (ATR) and checkpoint kinase 1 (CHK1) kinases. This review article describes the role of ATR and its major downstream target, CHK1, in the DDR and why cancer cells are particularly reliant on the ATR-CHK1 pathway, providing the rationale for targeting these kinases, and validation of this hypothesis by genetic manipulation. The recent development of specific inhibitors and preclinical data using these inhibitors not only as chemosensitisers and radiosensitisers but also as single agents to exploit specific pathologies of tumour cells is described. These potent and specific inhibitors have now entered clinical trial and early results are presented.

Keywords: ATR; CHK1; DNA-damage; DNA-repair; cell cycle; chemotherapy-sensitising-agents; protein-kinase-inhibitors; radiation-sensitising-agents.

PubMed Disclaimer

Conflict of interest statement

Nicola Curtin has received funding from Vertex pharmaceuticals and worked in collaboration with Vernalis on V158411. The other authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Induction of ATR-CHK1 pathway activation and downstream signalling. (A) Anti-metabolites such as hydroxyurea (HU) and gemcitabine deplete the dNTP pool and cause stalled replication forks [13,14,15]. Topoisomerase 1 poisons and monofunctional DNA alkylating agents cause single strand lesions that can also stall/collapse replication forks. This increases replication stress and the availability of ss-DNA for ATR activation. Poly-cyclic aromatic hydrocarbon induced bulky DNA adducts and intra-strand cross-links resulting from agents such as UV and platinum based chemotherapy drugs are repaired by NER, leaving behind a short strand of ss-DNA [16,17]. The ssDNA is also present at the site of IR or topoisomerase II poison induced DSBs that have been resected by exo- or endo-nucleases [18]. In all cases the ssDNA is first coated by RPA. (B) RPA enables localisation of ATR to sites of DNA damage [10]. ATR recognition of the RPA-ssDNA complex is dependent on ATR-interacting protein (ATRIP). Localisation of the 9-1-1 complex via RPA interaction with RAD17 and subsequent recruitment of TOPBP1 and claspin leads to ATR activation and subsequent phosphorylation events leading to cell cycle arrest and DNA repair [9,15]. CHK1 acts as an intermediary in many of the DNA repair and DNA checkpoint reactions resulting from the activation of ATR and contributes to fork stabilisation and inhibiton of replication origin firing.

Similar articles

Cited by

References

    1. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell. 2011;144:646–674. doi: 10.1016/j.cell.2011.02.013. - DOI - PubMed
    1. Curtin N.J. DNA repair dysregulation from cancer driver to therapeutic target. Nat. Rev. Cancer. 2012;12:801–817. doi: 10.1038/nrc3399. - DOI - PubMed
    1. O’Sullivan Coyne G., Chen A.P., Meehan R., Doroshow J.H. PARP Inhibitors in Reproductive System Cancers: Current Use and Developments. Drugs. 2017;77:113–130. doi: 10.1007/s40265-016-0688-7. - DOI - PMC - PubMed
    1. Massague J. G1 cell-cycle control and cancer. Nature. 2004;432:298–306. doi: 10.1038/nature03094. - DOI - PubMed
    1. Takai H., Tominaga K., Motoyama N., Minamishima Y.A., Nagahama H., Tsukiyama T., Ikeda K., Nakayama K., Nakanishi M., Nakayama K. Aberrant cell cycle checkpoint function and early embryonic death in Chk1(−/−) mice. Genes Dev. 2000;14:1439–1447. - PMC - PubMed